Almac Group’s Diagnostics business has identified a novel immune response mechanism in breast tumors deficient in DNA repair. The current study explains the molecular basis of this 44-gene immune based assay and demonstrates that the genes in the assay reflect activation of the innate immune response cGAS/STING/TBK1/IRF3 pathway in response to DNA damage.   The study provides rationale for the observed link between DNA repair deficiency and activation of the immune checkpoint PD-L1. Almac will...